Literature DB >> 23605168

Update on the treatment of juvenile idiopathic arthritis.

Julia G Harris1, Elizabeth A Kessler, James W Verbsky.   

Abstract

Juvenile idiopathic arthritis (JIA) is one of the most common chronic diseases of childhood. Although the pathophysiology behind this disease is poorly understood, there are effective treatments for JIA based on the subtype of disease. Treatment options include non-steroidal anti-inflammatory drugs, intra-articular glucocorticoid injections, and traditional disease modifying anti-rheumatic drugs such as methotrexate. In the past decade, the use of biologic therapy in JIA, including tumor necrosis factor inhibitors, interleukin-1 inhibitors, and interleukin-6 inhibitors, has dramatically increased with promising outcomes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23605168      PMCID: PMC3729726          DOI: 10.1007/s11882-013-0351-2

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  66 in total

1.  A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies.

Authors:  R Burgos-Vargas; J Vázquez-Mellado; C Pacheco-Tena; A Hernández-Garduño; M V Goycochea-Robles
Journal:  Ann Rheum Dis       Date:  2002-10       Impact factor: 19.103

2.  Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group.

Authors:  M A van Rossum; T J Fiselier; M J Franssen; A H Zwinderman; R ten Cate; L W van Suijlekom-Smit; W H van Luijk; R M van Soesbergen; N M Wulffraat; J C Oostveen; W Kuis; P F Dijkstra; C F van Ede; B A Dijkmans
Journal:  Arthritis Rheum       Date:  1998-05

3.  Preliminary definition of improvement in juvenile arthritis.

Authors:  E H Giannini; N Ruperto; A Ravelli; D J Lovell; D T Felson; A Martini
Journal:  Arthritis Rheum       Date:  1997-07

Review 4.  The place of corticosteroid therapy in juvenile chronic arthritis in 1992.

Authors:  A M Prieur
Journal:  J Rheumatol Suppl       Date:  1993-04

5.  JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production.

Authors:  Timothy P LaBranche; Michael I Jesson; Zaher A Radi; Chad E Storer; Julia A Guzova; Sheri L Bonar; Janice M Thompson; Fernando A Happa; Zachary S Stewart; Yutian Zhan; Chris S Bollinger; Prashant N Bansal; Jeremy W Wellen; Dean P Wilkie; Steven A Bailey; Peter T Symanowicz; Martin Hegen; Richard D Head; Nandini Kishore; Gabriel Mbalaviele; Debra M Meyer
Journal:  Arthritis Rheum       Date:  2012-11

6.  Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis.

Authors:  Ekaterina I Alexeeva; Saniya I Valieva; Tatyana M Bzarova; Elena L Semikina; Kseniya B Isaeva; Alexander O Lisitsyn; Rina V Denisova; Evgeniya G Chistyakova
Journal:  Clin Rheumatol       Date:  2011-03-08       Impact factor: 2.980

7.  Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis.

Authors:  P Woo; T R Southwood; A M Prieur; C J Doré; J Grainger; J David; C Ryder; N Hasson; A Hall; I Lemelle
Journal:  Arthritis Rheum       Date:  2000-08

8.  An autoinflammatory disease due to homozygous deletion of the IL1RN locus.

Authors:  Sreelatha Reddy; Shuang Jia; Rhonda Geoffrey; Rachel Lorier; Mariko Suchi; Ulrich Broeckel; Martin J Hessner; James Verbsky
Journal:  N Engl J Med       Date:  2009-06-04       Impact factor: 91.245

9.  Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.

Authors:  Nicolino Ruperto; Daniel J Lovell; Pierre Quartier; Eliana Paz; Nadina Rubio-Pérez; Clovis A Silva; Carlos Abud-Mendoza; Ruben Burgos-Vargas; Valeria Gerloni; Jose A Melo-Gomes; Claudia Saad-Magalhães; Flavio Sztajnbok; Claudia Goldenstein-Schainberg; Morton Scheinberg; Immaculada Calvo Penades; Michael Fischbach; Javier Orozco; Philip J Hashkes; Christine Hom; Lawrence Jung; Loredana Lepore; Sheila Oliveira; Carol A Wallace; Leonard H Sigal; Alan J Block; Allison Covucci; Alberto Martini; Edward H Giannini
Journal:  Lancet       Date:  2008-07-14       Impact factor: 79.321

10.  Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.

Authors:  Daniel J Lovell; Nicolino Ruperto; Steven Goodman; Andreas Reiff; Lawrence Jung; Katerina Jarosova; Dana Nemcova; Richard Mouy; Christy Sandborg; John Bohnsack; Dirk Elewaut; Ivan Foeldvari; Valeria Gerloni; Jozef Rovensky; Kirsten Minden; Richard K Vehe; L Wagner Weiner; Gerd Horneff; Hans-Iko Huppertz; Nancy Y Olson; John R Medich; Roberto Carcereri-De-Prati; Melissa J McIlraith; Edward H Giannini; Alberto Martini
Journal:  N Engl J Med       Date:  2008-08-21       Impact factor: 91.245

View more
  8 in total

Review 1.  Pediatric macrophage activation syndrome, recognizing the tip of the Iceberg.

Authors:  Courtney Crayne; Randy Q Cron
Journal:  Eur J Rheumatol       Date:  2019-12-03

2.  Prescribing Patterns and Impact of Factors Associated with Time to Initial Biologic Therapy among Children with Non-systemic Juvenile Idiopathic Arthritis.

Authors:  Xiaomeng Yue; Bin Huang; Ana L Hincapie; Patricia R Wigle; Tingting Qiu; Yuxiang Li; Esi M Morgan; Jeff J Guo
Journal:  Paediatr Drugs       Date:  2021-03-02       Impact factor: 3.022

3.  Effect of methotrexate on the mandibular development of arthritic rabbits.

Authors:  Thomas Michael Präger; Philipp Meyer; Smbat Rafayelyan; Kirsten Minden; Paul-Georg Jost-Brinkmann
Journal:  Eur J Orthod       Date:  2014-12-17       Impact factor: 3.075

Review 4.  Macrophage activation syndrome and cytokine-directed therapies.

Authors:  Grant S Schulert; Alexei A Grom
Journal:  Best Pract Res Clin Rheumatol       Date:  2014-04       Impact factor: 4.098

Review 5.  The Immunology of Macrophage Activation Syndrome.

Authors:  Courtney B Crayne; Sabrin Albeituni; Kim E Nichols; Randy Q Cron
Journal:  Front Immunol       Date:  2019-02-01       Impact factor: 7.561

6.  Synovial-Fluid miRNA Signature for Diagnosis of Juvenile Idiopathic Arthritis.

Authors:  Nadége Nziza; Eric Jeziorski; Marion Delpont; Maïlys Cren; Hugues Chevassus; Aurélia Carbasse; Perrine Mahe; Hamouda Abassi; Pauline Joly-Monrigal; Eric Schordan; Alain Mangé; Christian Jorgensen; Florence Apparailly; Isabelle Duroux-Richard
Journal:  Cells       Date:  2019-11-26       Impact factor: 6.600

Review 7.  B Cells on the Stage of Inflammation in Juvenile Idiopathic Arthritis: Leading or Supporting Actors in Disease Pathogenesis?

Authors:  Rita A Moura; João Eurico Fonseca
Journal:  Front Med (Lausanne)       Date:  2022-04-04

8.  Intake of high fructose corn syrup sweetened soft drinks, fruit drinks and apple juice is associated with prevalent coronary heart disease, in U.S. adults, ages 45-59 y.

Authors:  Luanne Robalo DeChristopher; Jaime Uribarri; Katherine L Tucker
Journal:  BMC Nutr       Date:  2017-06-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.